'%20fill='%23224a7c'/%3e%3c/clipPath%3e%3cclipPath%20id='clip-path-2'%3e%3cpath%20id='Path_4394'%20d='M4.892,12.4c.758.192,1.629.412,2.67.6a27,27,0,0,0,5.02.426,18.387,18.387,0,0,0,4.07-.6,15.613,15.613,0,0,1,3.2-.6,2.179,2.179,0,0,1,1.861.814,3.668,3.668,0,0,1,.542,1.724c.058.524.058.872.35,1.086a3.609,3.609,0,0,0,1.821.31c.95.02,2.268-.02,3.12-.058s1.24-.077,1.531.1a1.153,1.153,0,0,1,.485.989,10.163,10.163,0,0,0-.136,1.3,2.4,2.4,0,0,0,.717,1.142,4.087,4.087,0,0,1,.872,1.222.844.844,0,0,1-.446,1.066,5.765,5.765,0,0,1-2.171.5,10.913,10.913,0,0,0-2.326.271c-.465.194-.426.581-.155.988s.776.833,1.028,1.3a1.084,1.084,0,0,1-.136,1.357,4.056,4.056,0,0,1-1.977.814c-.814.155-1.667.194-2.442.329a12.864,12.864,0,0,0-1.978.543c-.5.175-.814.291-.969.621a.85.85,0,0,0,.427,1.163,13.866,13.866,0,0,0,2.616.5c.872.175,1.453.484,1.55,1.047a13.544,13.544,0,0,1-.368,2.229,3.628,3.628,0,0,0,.523,2.267,1.967,1.967,0,0,0,1.589.755,8,8,0,0,0,2.364-.077,8.558,8.558,0,0,0,1.822-.736,1.836,1.836,0,0,1,1.861-.1,4.294,4.294,0,0,1,1.182,2.326c.194.872.155,1.569.891,2.015a14.815,14.815,0,0,0,3.664.93A14,14,0,0,1,41.4,42.242a9.687,9.687,0,0,1,1.736,1.229A24.91,24.91,0,1,0,4.892,12.4'%20transform='translate(-4.892%20-0.176)'%20fill='%23224a7c'/%3e%3c/clipPath%3e%3c/defs%3e%3cg%20id='Group_3541'%20transform='translate(-0.094%20-0.128)'%3e%3cg%20id='Group_3282'%20transform='translate(0.094%2015.73)'%3e%3cg%20id='Group_3281'%20clip-path='url(%23clip-path)'%3e%3crect%20id='Rectangle_2848'%20width='33.837'%20height='20.982'%20transform='translate(-0.094%2033.75)%20rotate(-89.841)'%20fill='%23224a7c'/%3e%3c/g%3e%3c/g%3e%3cg%20id='Group_3284'%20transform='translate(3.563%200.128)'%3e%3cg%20id='Group_3283'%20clip-path='url(%23clip-path-2)'%3e%3crect%20id='Rectangle_2849'%20width='43.423'%20height='46.468'%20transform='translate(-0.12%2043.294)%20rotate(-89.841)'%20fill='%23224a7c'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
The FY2025 (Dec) proxy of Kura Oncology names 18 peer companies for pay. Among Kura Oncology and these peers, CEO pay was 8th highest of 9 and total shareholder return was 7th highest of 9.
8th highest of 9in Kura Oncology and its pay peers, FY2025 (Dec) by CEO pay:
$4.6M$27.8M
7th highest of 9in Kura Oncology and its pay peers, FY2025 (Dec) by total shareholder return:
$14$414
Pay peer group, FY2025 (Dec) proxy
| Cogent Biosciences | ||
| Revolution Medicines | ||
| Arcus Biosciences | ||
| IDEAYA Biosciences | ||
| Kymera Therapeutics | ||
| Structure Therapeutics | ||
| Arvinas | ||
| Relay Therapeutics | ||
| Crinetics Pharmaceuticals | Not disclosed | Not disclosed |
| Day One Biopharmaceuticals | Not disclosed | Not disclosed |
| Iovance Biotherapeutics | Not disclosed | Not disclosed |
| Janux Therapeutics | Not disclosed | Not disclosed |
| Nuvalent | Not disclosed | Not disclosed |
| SpringWorks Therapeutics | Not disclosed | Not disclosed |
| Summit Therapeutics | Not disclosed | Not disclosed |
| Syndax Pharmaceuticals | Not disclosed | Not disclosed |
| Xencor | Not disclosed | Not disclosed |
| iTeos Therapeutics | Not disclosed | Not disclosed |
'%20fill='%23FEFEFE'%3e%3cpath%20d='M67.7444739,25%20L33.1043073,38.2478027%20L34.7958615,41.1131448%20L41.0490807,51.7151219%20L29.0986607,51.7151219%20L28,54.6065381%20L57.1428867,79%20L60.0675871,77.3612019%20L46.8800441,55.0029363%20L63.0277166,55.0032886%20L63.8216155,51.7151219%20L70,26.9178624%20L67.7444739,25%20Z%20M38,39.9222264%20L66,29%20L60.3908123,52%20L44.9725093,52%20L38,39.9222264%20Z%20M34,55%20L43.1090246,55%20L52,70%20L34,55%20Z'%20id='Fill-1-Copy'/%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
18 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.